Current interventional options for palliative care for patients with advanced-stage cholangiocarcinoma

Abstract

Primary biliary tract tumors are malignancies that originate in the liver, bile ducts, or gallbladder. These tumors often present with jaundice of unknown etiology, leading to delayed diagnosis and advanced disease. Currently, several palliative treatment options are available for primary biliary tract tumors. They include percutaneous transhepatic biliary drainage (PTBD), biliary stenting, and surgical interventions such as biliary diversion. Systemic therapy is also commonly used for the palliative treatment of primary biliary tract tumors. It involves the administration of chemotherapy drugs, such as gemcitabine and cisplatin, which have shown promising results in improving overall survival in patients with advanced biliary tract tumors. PTBD is another palliative treatment option for patients with unresectable or inoperable malignant biliary obstruction. Biliary stenting can also be used as a palliative treatment option to alleviate symptoms in patients with unresectable or inoperable malignant biliary obstruction. Surgical interventions, such as biliary diversion, have traditionally been used as palliative options for primary biliary tract tumors. However, biliary diversion only provides temporary relief and does not remove the tumor. Primary biliary tract tumors often present in advanced stages, making palliative treatment the primary option for improving the quality of life of patients.

Key Words: Cholangiocarcinoma; Palliative care; Endoscopic treatment; Surgery; Complications; Interventional radiology

Core Tip: Nowadays, we still see a high incidence of primary biliary tract tumors arriving at emergency departments with a clinical picture of jaundice of unknown etiology. Unfortunately, when jaundice is diagnosed, most patients already show signs of advanced disease. It is up to the attending physician to offer the best alternatives for palliative treatment for a better quality of life of patients. The aim of this study is to evaluate the interventional palliative treatment options currently used to clinically improve symptoms and their results and related complications.

INTRODUCTION

Cholangiocarcinoma (CCA) is a malignant tumor of the epithelial cells of the biliary tract[1]. CCAs can be divided into three forms: intrahepatic CCA (iCCA), distal extrahepatic CCA (eCCA), and perihilar pCCA[2,3]. Similarities exist among these three forms, but key differences lead to distinct outcomes[3]. CCA is considered a very aggressive tumor that presents with a poor prognosis by the time it is diagnosed[4]. Surgical resection is the only meaningful option for the possible treatment of CCA. Patients who are not candidates for surgery are considered for palliative care treatment[4].

The main goal of palliative care is to enhance the quality of life of patients[5]. Only a few patients who present with CCA are candidates for surgical treatment[6]. It has been reported that less than 20% of patients diagnosed with iCCA are eligible for surgical resection[7]. Appropriate palliative care treatments in CCA are influenced by the classification of the tumor[8]. Current palliative options include biliary stenting, chemotherapy, radiofrequency ablation, and photodynamic therapy[8]. Adverse effects are associated with some of these palliative treatments[8], and a full comprehensive understanding of the benefits and risks of current palliative treatment options will help clinicians determine the most appropriate course of action.

RISK FACTORS

The risk factors for the incidence of CCA include primary sclerosing cholangitis, parasitic infections, toxins, bile duct cysts, hepatolithiasis, hepatic cirrhosis, and viral hepatitis[9,10]. In addition, there may be evidence that certain genetic polymorphisms regulate the risk of CCA[10]. Diabetes and heavy alcohol ingestion may increase the risk of CCA[9]. CCA in Asian countries is significantly associated with the liver flukes Clonorchis sinensis and Opisthorchis viverrini[11]. The effects of hepatitis B and hepatitis C on the incidence of CCA have not been completely studied[11]. Surveillance of risk factors for CCA needs to be established as it may facilitate better prognosis for patients.

EPIDEMIOLOGY

The epidemiology of CCA differs depending on factors such as geography, risk factors, and age. The largest incidence of CCA is in Asia, with the highest occurring in parts of Thailand[12]. The incidence rates in Western countries are lower than those in Asian countries[12].

The prognosis of CCA is poor, with the only curative option being surgical resection in early-stage tumors[13]. The mortality rate of CCA has increased significantly in recent years, up to a 36% increase in mortality from 1999 to 2014 in a United States-based study[14]. The 5-year survival rates for certain CCAs range from 5% to 10%[15]. Some studies have described the percentage of resectable CCAs. In a cohort study describing hilar CCAs, research has shown that only 26% of hilar CCAs are resectable[16]. It has also been reported that only 15% of patients with iCCA present with a resectable tumor at the time of diagnosis[17]. Therefore, the importance of palliative care in CCA cannot be understated and must be fully explored and understood to deliver the most appropriate individualized care for each patient.

CLINICAL PRESENTATION

The clinical presentation of CCA depends on the type, stage, and location of the tumor. The most common presentation of CCA is jaundice, which manifests as a yellowish pigmentation of the skin and mucous membranes[18]. However, in iCCA, because tumor growth is intrahepatic, patients are usually asymptomatic and jaundice only manifests at later stages because obstruction is less frequent[19]. Studies have shown that jaundice is reported as an initial symptom of iCCA in only 10%-15%[18] of cases and that the diagnosis of early-stage iCCA represents an incidental finding in almost 25% of cases[20]. Other clinical symptoms associated with the onset of iCCA are nonspecific and include the following: Malaise, cachexia, dull right upper quadrant abdominal pain, and night sweats[20]. Conversely, most eCCAs and pCCAs are associated with biliary obstruction. It has been estimated that 90% of eCCA cases present with symptoms of obstructive jaundice[21], which include jaundice, pale stools, dark urine, and pruritis. A cohort study demonstrated that bilirubin levels are significantly more elevated in eCCA and pCCAs than in iCCA because of the larger frequency of biliary obstruction[22]. During the course of the disease, patients with eCCA present with nonspecific symptoms similar to iCCA, such as weight loss, abdominal pain, night sweats, fatigue, emesis, vomiting, and loss of appetite, in addition to an increase in cholestasis laboratory findings[23].

On physical examination, eCCA is characterized by jaundice, hepatomegaly, and a palpable gallbladder (Courvoisier sign) whereas iCCA usually presents mainly with right upper quadrant tenderness[24]. CCA has also been associated with rare cutaneous manifestations, including sweet syndrome, erythema multiforme, and porphyria cutanea tarda[24]. However, these findings are nonspecific and can be found in other pathologies. Therefore, a definitive diagnosis of CCA requires further laboratory and imaging investigations.

DIAGNOSIS

The diagnosis and early detection of CCA remain challenging. It is important to check bilirubin, alkaline phosphatase (ALP), gamma-glutamyl transpeptidase (GGT), alanine transaminase (ALT), and aspartate aminotransferase (AST) levels in all suspected patients. In patients with eCCA, bilirubin, ALP, and GGT levels are elevated, whereas in patients with iCCA, ALP level is atypical, but the other values are within normal ranges[24]. In the early stages of CCA, ALT and AST levels are normal, but as the disease progresses, they increase because of the hepatocellular damage caused by cholestasis[24]. Blood biomarkers are also useful for detecting CCA. Cancer antigen 19-9 (CA 19-9) is an important prognostic factor at presentation and has been associated with poor prognosis[22]. However, the use of CA 19-9 is limited as it has low specificity in distinguishing malignant from benign pathologies, and it is absent in patients with deficient Lewis antigen[24]. Carcinoembryonic antigen and alpha fetoprotein can also be used, but both have shown limited specificity and sensitivity.

The diagnosis of CCA relies heavily on imaging modalities. Transabdominal ultrasound is often employed as an initial imaging modality for CCA diagnosis in patients with obstructive jaundice because it is beneficial for examining the origins of bile duct obstruction and characterizing liver lesions[25]. In addition to detecting CCA, this allows the exclusion of more common etiologies for obstruction jaundice such as choledocholithiasis. With new advancements in technology, the use of contrast-enhanced ultrasound has demonstrated significant potential in assessing both luminal and extraluminal masses in the diagnosis of CCA[25]. Computed tomography (CT) is conducted in 90% of cases with possible CCA diagnosis[25]. CT plays an important role during the initial evaluation of CCA: It demonstrates features such as the extent of the tumor, it ascertains the potential of surgical resectability, and it allows the estimation of prognostic pathological factors, including vascular infiltration and the presence of lymph node metastasis[25]. The two most commonly used imaging techniques after the identification of the tumor are endoscopic retrograde cholangiopancreatography (ERCP) and magnetic resonance cholangiopancreatography (MRCP)[21]. MRCP is the preferred modality because it allows the accurate assessment of tumor resectability[26]. Endoscopic ultrasound (EUS) and fine needle aspiration guided by EUS have also been reported to help with the diagnosis and staging of CCA[26]. ERCP is still widely used and preferred by some physicians and surgeons because it allows cytological sampling and histological confirmation of the malignancy[21,24].

PALLIATIVE TREATMENT DEFINITION

Palliative care is a medical holistic approach that aims to enhance the well-being of patients who are confronting challenges related to incurable life-threatening illnesses by preventing and alleviating physical, psychological, and spiritual suffering[27]. Palliative care should involve interdisciplinary teams with excellent communication skills to support patients and their families[27]. In patients with CCA with a locally advanced, unresectable, or recurrent tumor, palliative care goals are to relieve symptoms of obstructive jaundice, pain, and pruritis[26].

In this review, we summarize recent findings on interventional procedures for the palliative care management of CCA. Different interventional options that are currently available and their benefits and complications are discussed. Systemic treatment, although available, is beyond the scope of this review.

MANAGEMENT

Palliative biliary drainage is used in advanced-stage CCA to alleviate symptoms such as pain, severe pruritus, and cholangitis. Patients with jaundice who are asymptomatic and have a life expectancy of less than 3 months are generally not candidates for biliary drainage procedures. Other purposes of palliative biliary drainage include improving functional status and liver function to enable subsequent systemic chemotherapy. This procedure encompasses three methods: percutaneous, endoscopic, and surgical bypass (Table 1).

Table 1 Palliative treatment options for cholangiocarcinoma and their associated techniques, indications, and complications.

Type	Technique	Indication	Complications
Percutaneous drainage	PTBD	Proximal malignant biliary obstructions (particularly Bismuth type III and IV peri-hilar CCA patients)	Catheter-related complications: wound care, hygiene maintenance, catheter dislodgement, and PTBD blockages
			Acute cholangitis, bleeding, and peri catheter leakage
	PTBS	Specific patients with malignant biliary obstruction	No catheter-related complications (due to no external drainage)
			Cholangitis, pancreatitis, bleeding, stent dysfunction, cholecystitis, duodenal perforation, stent obstruction (due to tumor overgrowth)
Endoscopic drainage	ERCP with biliary stenting	Patients with incurable conditions (e.g. Unresectable tumors, malignant hilar obstruction)	Stent occlusion or dysfunction (mainly due to tumor ingrowth)
	EUS-EBD	Cases where ERCP may be difficult due to anatomical variations, altered anatomy from prior surgeries or tumor infiltration	Minimal complications including pancreatitis and cholecystitis
Surgical Drainage (only considered as a final option after failure of other approaches)	Choledochojejunostomy	Distal CCA	High perioperative morbidity and mortality
	Intrahepatic bile duct bypass	Peri hilar CCA
	Extrahepatic bile duct bypass	Distal obstruction or Bismuth type I
	Left hepaticojejunostomy	Bismuth type IIIa
	Right hepaticojejunostomy	Bismuth type IIIb
	Right or left sectoral duct bypass	Bismuth type IV	High perioperative morbidity and mortality
			Frequently ineffective due to inadequacy of a single anastomosis to drain a sufficient volume of functioning liver

PTBD: Percutaneous transhepatic biliary drainage; PTBS: Percutaneous transhepatic biliary stenting; ERCP: Endoscopic retrograde cholangiopancreatography; EUS-EBD: Endoscopic ultrasound guided endoscopic biliary drainage; CCA: Cholangiocarcinoma.

PERCUTANEOUS PALLIATIVE BILIARY DRAINAGE

The percutaneous method for palliative biliary drainage involves a guided puncture using ultrasonography aiming to place a catheter into the dilated bile ducts. This approach includes two techniques: percutaneous transhepatic biliary drainage (PTBD) and percutaneous transhepatic biliary stenting (PTBS). Palliative PTBD plays a crucial role in decompressing the biliary system specially in proximal obstructions, particularly in cases of Bismuth type III and IV perihilar CCA. Research suggests that PTBD has a higher success rate in therapy with fewer complications related to cholangitis compared with the endoscopic approach[28]. However, wound care, catheter displacement, blockages, and even hygiene maintenance may represent a challenge for some patients. To address these challenges, patients receive catheter care training before hospital discharge[28,29]. Complications may include acute cholangitis, bleeding, and pericatheter leakage.

Palliative PTBS is a procedure aimed at managing jaundice and serves as an optional treatment for specific patients with malignant biliary obstruction. The main advantage of this procedure is to restore the physiological pathway to the biliary drainage to the duodenum and minimize the loss of bile salts and electrolytes. This is achieved using either plastic or metallic stents. Studies have indicated that PTBS, particularly with the implantation of self-expandable metallic stents (SEMS), has better efficacy than catheter drainage. PTBS can effectively reduce complications associated with catheter usage and can improve the overall quality of life of patients by eliminating the need for external drainage. Metal stents have a larger diameter, present a better long-term patency, and are more cost-effective compared with plastic ones. In the palliative care of advanced hilar CCA (Bismuth III and IV), percutaneous stenting outcomes exceed those by endoscopy[30-33].

The PTBS procedure is performed under local anesthesia and moderate sedation. This procedure involves inserting a 0.035 in guidewire into the previously placed PTBD and then replacing the PTBD catheter with 5 French diagnostic catheters (specifically Cobra catheters). The tract passing through the obstructed region into the duodenum is cannulated using a 0.035 in guidewire, followed by the introduction of a metallic stent. Typically, pre stent dilation of malignant biliary strictures is avoided to prevent tumoral bleeding that might result in early stent blockage[34]. After stent placement, an internal-external drainage catheter (temporary close catheter hub) is inserted as a precautionary measure in case of stent malfunction. Follow-up after biliary stenting includes clinical assessment and laboratory investigations at the two-week mark. A cholangiogram through the internal-external drainage catheter is performed after two weeks to assess stent patency, followed by the removal of the internal-external drainage catheter.

The most frequent early complications after percutaneous procedures are cholangitis, pancreatitis, and bleeding. Stent dysfunction, bleeding, cholecystitis, and less frequently, duodenal perforation are usually the most frequent late ones. The major complication of biliary stenting is recurrent jaundice or cholangitis resulting from stent obstruction. Biliary sludge and tumor ingrowth through the stent are the primary causes of obstruction[35].

ENDOSCOPIC APPROACH

Selecting the type of stent for palliative drainage involves different factors to be considered, like the location of the obstruction, the patient’s prognosis, the risk of potential stent complications such as blockage or movement, the preference of the endoscopist, and the availability of different stent types. In cases where hilar obstruction is presented like in hilar tumors, multidisciplinary teamwork is a must for its management. Relieve the obstruction of the bile ducts in advanced unresectable hilar tumors may be challenge and usually requires multiple endoscopic and/or percutaneous procedures[36,37].

Typically for the cases with hilar obstruction ERCP with uncovered SEMS represents the standard of care to prevent drainage blockage from the opposite biliary system. Similarly, in the treatment of hilar obstruction, the use of uncovered SEMS is recommended to prevent blockage of the left or right hepatic duct[37].

Uncovered SEMS offer notable advantages over plastic stents, primarily due to their wire mesh design that remains open and does not obstruct the side branches of the intrahepatic bile duct. They also feature a delivery system that allows passage through tight biliary strictures, such as a sharp tip, enabling the use of stents with reduced diameter sizes, which is particularly beneficial for lesions located proximally[37,38].

Several studies demonstrated that for patients with hilar obstructions SEMS provides higher clinical success rates as well as less need for reinterventions when compared to plastic stents[31,38-42]. In one trial involving 188 patients diagnosed with unresectable hilar CCA, the rates of success using SEMS comparing with plastic stents regarding drainage was 70% vs 46% and the authors also observed a prolonged overall survival (median 126 vs 49 d)[42]. Another study with 60 patients demonstrated that SEMS had superior patency rates at six months (81% vs 20%) and required fewer reinterventions (0.63 vs 1.80 interventions per patient)[39].

In cases of unresectable cancer with obstructed hilar regions, the placement of bilateral SEMS represents the standard approach when technically feasible to optimize biliary drainage, particularly when both liver lobes are affected by obstruction. Before the ERCP procedure, imaging techniques such as CT or MRCP must be available to identify the dominant biliary system, allowing the endoscopy team to plan, in case the bilateral stenting is not possible, to which of the ducts the stent should place to provide adequate bile drainage.

The efficacy of drainage is affected by the amount of drained liver volume[33,43,44]. Previously, it was commonly accepted that draining a minimum of 25% of the liver volume was required to relieve jaundice. However, recent research suggests that draining more than 50% of the total liver volume (assessed via CT) is associated with enhanced overall survival. If a single stent fails to alleviate symptoms by draining more than 50% of the total liver volume, the consideration of ERCP-guided bilateral stenting and/or percutaneous drainage may be warranted[44].

For certain patients, the placement of a single, unilateral stent provides adequate drainage and relief from symptoms. However, it remains uncertain whether bilateral drainage offers superior outcomes compared with unilateral placement[45-47]. A meta-analysis of seven studies involving more than 600 patients diagnosed with tumoral hilar obstruction suggested that bilateral stenting did not significantly differ from unilateral stenting in terms of clinical response rates, stent occlusion, cholangitis, or patient mortality[45]. Nevertheless, another study involving 133 patients that were treated with SEMS revealed that patients that had bilateral stents had a lower chance of failure when compared to unilateral ones. (hazard ratio, 0.30; 95%CI, 0.17-0.52)[46].

The primary long-term complication encountered after placing SEMS for malignant biliary obstruction is stent occlusion. The diagnosis of stent dysfunction typically involves the presence of two of the following three specified criteria:

Dilatation of the bile duct system demonstrated by ultrasound.

Abnormal elevation of serum bilirubin levels (≥ 2 mg/dL) with an increase of ≥ 1 mg/dL compared with the value following the initial successful drainage.

Increase in ALP/gamma-glutamyl transferase to more than double the upper limit of normal values with an increase of at least 30 U/L.

Manifestations of cholangitis[47]

Tumor ingrowth represents the main reason for stent occlusion and it is more related to uncovered SEMS[42]. Furthermore, this overgrowth, will involves the blockage of the stent’s proximal or distal ends, contributes to long-term stent occlusion. Occasionally, obstruction due to sludge, mucus, or debris may occur, but it typically occurs together with the progression of the tumor itself.

The average functional duration of this prothesis ranges between 5 and 6 months[48,49] before obstruction occurs. Managing occluded stents involves various methods such as balloon mechanical cleaning, placement of plastic or metallic stents, and endobiliary radiofrequency ablation. Mechanical cleaning is suitable for debris occlusion but should be combined with other procedures when tumor ingrowth is present. Placement of a second plastic stent has a shorter patency period, typically lasting 60-90 d, compared with the patency period of 100 d for second SEMS placements[42]. Endobiliary radiofrequency ablation is an innovative intervention used to safely ablate ingrown tumors within the stent lumen, leading to long-term patency comparable to SEMS placement[49]. The advantage of this procedure is to not compromise the stent lumen and represents a benefit comparing to the placement of a second stent that may decrease its diameter.

Retrospective studies that compare the safety and effectiveness of percutaneous treatment vs endoscopic treatment for obstructed hilar bile ducts have shown that percutaneous interventions lead to a faster therapeutic decrease in bilirubin levels, fewer instances of infections, and reduced need for repeated drainage procedures[50-53]. Among patients with tumors in the hilar region who undergo endoscopic treatment, those who receive a unilateral stent-particularly when both sides of the liver’s bile ducts have been visualized with contrast-experience notably poorer survival rates compared to patients with bilateral stents[54]. Furthermore, the risk of post endoscopy cholangitis increases with the extent of isolation caused by the hilar tumor, with Bismuth I patients having only a 4% risk and Bismuth III and IV patients having a nearly 60% risk[55]. Another study comparing the outcome of endoscopic vs percutaneous drainage in patients with advanced type III or IV hilar CCA concluded that the percutaneous SEMS group exhibited a notably higher success rate in biliary decompression compared to the endoscopic SEMS group (92.7% vs 77.3%, respectively, P = 0.049). Although the overall occurrence of procedure-related complications was comparable between both groups, one fatality resulting from biliary sepsis was recorded in the endoscopic SEMS group. Patients who initially achieved successful biliary drainage, regardless of the procedure used, experienced substantially longer median survival than those for whom biliary drainage failed (8.7 vs 1.8 months, respectively, P < 0.001). Once successful biliary decompression was attained, and the median survival and duration of stent patency were similar in both study groups[52].

In cases of advanced malignant hilar strictures (Bismuth III and IV), the percutaneous method for biliary drainage is favored over the endoscopic approach because of its notably higher success rate (93% compared to 77%, with a P value of 0.049) and reduced incidence of cholangitis related to the procedure. In addition, the percutaneous approach enables the precise selection of the affected lobe for drainage[52].

EUS GUIDED ENDOSCOPIC BILIARY DRAINAGE

EUS provides real-time imaging with high resolution and has the ability to visualize the bile ducts and adjacent structures in great detail. EUS guided endoscopic biliary drainage (EUS-EBD) combines the advantages of EUS and biliary drainage, allowing the accurate placement of stents or drainage catheter under direct visualization. This technique is valuable in cases where conventional ERCP may be challenging because of anatomical variations, altered anatomy from prior surgeries, or tumor infiltration.

The EUS-EBD procedure involves passing an echoendoscope through the gastrointestinal tract to access the duodenum and visualize the biliary tree using ultrasound. Once the target area is identified, a guidewire is advanced through the obstructed bile duct under EUS guidance. Following successful guidewire placement, a biliary stent or drainage catheter is deployed to relieve the obstruction and alleviate symptoms such as jaundice and pruritus. The main benefits of EUS-EBD are improved visualization, precise guidance, real-time ultrasound guidance, enhanced precision of wire placement, reduced risk of complications, overcoming anatomical challenges, and permitting navigation through anatomical variations or distorted anatomy caused by the tumor, making it a valuable option in complex cases.

Several studies have demonstrated the efficacy and safety of EUS-EBD in the palliative care of patients with advanced CCA. Notable outcomes include successful drainage, symptom relief, and improved quality of life. Comparative studies have shown that EUS-EBD can be as effective as or even superior to traditional ERCP in certain cases[56,57].

Surgical approach

Surgical bypass procedures have demonstrated a significant increase in perioperative mortality, ranging from 0% to 17%, and morbidity, with rates between 17% and 55%[58]. Nowadays the surgical approach will only be considered if other options like percutaneous and/or endoscopic treatments are not available or fail. In instances where laparotomy reveals distant metastases, surgical bypass may be considered. Choledochojejunostomy is a feasible surgical bypass procedure for distal obstructions, whereas intrahepatic bile duct bypass is appropriate for perihilar CCA. Extrahepatic bile duct bypass, although technically less challenging, is associated with lower morbidity and is suitable for distal obstructions or Bismuth type I in the perihilar region. Palliative surgical bypass for perihilar CCA involves intricate surgeries tailored to each tumor type. According to the location of the tumoral obstruction, left or right main ducts, the surgeon will proceed with either a left of right hepaticojejunostomy. Bismuth type IV may requires right or left sectoral duct bypass. However, surgical bypass for this type of tumors are often ineffective because of the inadequacy of a single anastomosis to drain a sufficient volume of functioning liver. Therefore, in cases of Bismuth IV, a bilateral hepaticojejunostomy bypass should be considered with exceptional selectivity[58].

Three randomized trials[59-61] that compared surgical bypass to endoscopic drainage demonstrated similar effectiveness in alleviating symptoms. However, endoscopic drainage exhibited fewer early complications, whereas surgical bypass presented fewer late complications. It is important to note that these trials focused on patients with a lower end block caused by pancreatic and periampullary carcinoma, which limits the direct extrapolation of these findings to patients with a hilar block. In the case of locally advanced gallbladder cancer with an average survival of 3-6 months, nonoperative methods might be more effective in alleviating symptoms[62]. Two randomized trials evaluated endoscopic and percutaneous drainage methods for malignant biliary obstruction[62,63]. Speer et al[63] demonstrated that endoscopic drainage surpassed percutaneous drainage in terms of successful drainage (81% vs 61%) and lower 30-d mortality (15% vs 33%). This trial included 75 patients, but only 29 had a hilar block. However, the less favorable outcomes associated with percutaneous stenting might be attributed to the use of a rigid external percutaneous transhepatic catheter for drainage, leading to increased morbidity and mortality. By contrast, Piñol et al[64] showed different results with higher successful drainage (71% vs 42%, P = 0.03) but more complications (61% vs 35%) with PTBD compared to endoscopic drainage. The median survival time significantly favored the PTBD group (3.7 vs 2 months, P = 0.02). In addition, they compared a metal stent placed percutaneously with a plastic stent placed endoscopically (Figure 1).

Figure 1 Current management options for palliative care of advanced cholangiocarcinoma. PTBD: Percutaneous transhepatic biliary drainage; PTBS: Percutaneous transhepatic biliary stenting; ERCP: Endoscopic retrograde cholangiopancreatography; EUS-EBD: Endoscopic ultrasound guided endoscopic biliary drainage; CCA: Cholangiocarcinoma.

CONCLUSION

The basis for the palliative treatment of advanced CCA relies on the alleviation of the obstructive symptoms related to the drainage of the biliary tract. Proper management must be defined by a multidisciplinary team that considers the radiological features of the tumor and the resources available in the institution. The results of systemic treatment for palliative care can be improved if the patient’s biliary tract has been properly drained using one of the presented techniques.